Cover Image
Market Research Report

India Pharma Outlook 2016: Milestones to Watch - Growth from Exports and Domestic Getting Better, Implementation of Policies under "Make-in-India", Overture of A New Ministry

Published by MP Advisors Product code 355095
Published Content info
Delivery time: 1-2 business days
Price
Back to Top
India Pharma Outlook 2016: Milestones to Watch - Growth from Exports and Domestic Getting Better, Implementation of Policies under "Make-in-India", Overture of A New Ministry
Published: March 17, 2016 Content info:
Description

2016 will be a crucial for drug makers and consumers. During ‘Make-in-India' week in Mumbai, Govt. highlighted many amendments or introduction of new policies with an aim to make India as a major hub for end to end drug discovery. To boost drug discovery, to promote manufacturing of certain drugs against life threatening diseases like AIDS, and to reduce our dependence on China, the Govt. has promised to offer many incentives (exemption from excise duty or tax) and also plans to setup venture capital funds, cluster developments to strengthen pharma infrastructure / business. Other developments or initiatives include, i) The voluntary Uniform code of Pharma marketing practice will be replaced with a mandatory code by June. This will stop the promotion of drug prior to receipt of the marketing approval and also the practice of drug makers offering gifts to doctors upon prescribing their products; ii) Concept of the ‘Online pharmacies' is also expected to be implemented during this year; iii) Change in FDI rule where investor now invest thru Automatic route rather taking any prior regulatory approval; iv) Growth in Medical Infrastructure which will increase accessibility to drug market to improve in Tier-II towns and rural areas.

Declined growth in bulk drugs due to regulatory scrutiny and rising competition & market factors from other Asian competing nations will be compensated by geographies expansion (e.g., Lupin, Cipla, Sun pharma) and sustainable growth from Domestic formulation (e.g. Alkem, Cipla, Sun pharma, Dr Reddy), mainly from Chronic diseases' segment, due to growth in urban population, better awareness on healthcare, and greater penetration of services. India pharma has started expanding in other regulated markets (Japan, Germany, France, Canada) and Tier-II countries (Brazil, Mexico, Venezuela, Russia, etc.). To explore further opportunities of growth, Indian pharma companies have started developing complex generics/ biosimilars. Almost all companies, among Top-20 list, have robust pipeline in this value chain, targeting primarily emerging markets; however, they are also capitalizing on their competitiveness and capabilities to enter into the regulated market.

Table of Contents

Table of Contents

  • Aurobindo Pharma - US BUSINESS AND INJECTABLES KEYS TO GROWTH - Looking to STRENGTHEN IN OTHER GEOGRAPHY TOO
  • Table 1: Aurobindo Pharma: GLOBAL REGULATORY FILINGS
  • Table 2: Aurobindo Pharma KEY ANDAs APPROVAL IN 1H16
  • New Aeras to Watch For: CADILA HEALTHCARE LTD: Future growth from NCE, Bio-Similars, Vaccines, Transdermal and Complex Generics
    • US REMAINS THE KEY GROWTH DRIVER FOR CDH
  • Table 1: Cadila Healthcare Ltd.
  • KEY TRANSDERMAL PRODUCTS
    • ONGOING STUDIES OF LIPAGLYN IN NASH
    • Clinical Data in NASH so far
    • Clinical Data in NASH so far
  • Cipla Ltd: Consolidation of Recent Acquisitions + Geographic Expansion of the Inhaler Business
  • Figure 1: Cipla Ltd.
  • GENERIC NEXIUM'S MARKET SHARE TREND
  • Table 1: Cipla Ltd.
  • INVAGEN'S SELECT PARA IV OPPORTUNITIES
  • Table 2: Cipla Ltd.
  • INVAGEN: HIGHEST MARKET SHARE PRODUCTS - TOP 5
    • Annexure: Cipla Ltd.
  • INVAGEN'S CURRENT PRODUCTS
    • DR REDDY'S LAB: Near-term Growth Muted: Strong Competition to Launched Products + No Significant Approvals + Remediation Costs related to FDA's WL
  • Figure 1: Dr. Reddy's Lab
  • PENDING ANDAs(76) BY DOSAGE FORM& SELECT OPPORTUNITIES
  • Table 1: Dr Reddy's Ltd.
  • FACING COMPETITION IN US: MARKET SHARE OF KEY INJECTABLES
  • Figure 2: Dr. Reddy's Lab
  • AURIGENE: INTERNAL PIPELINE
    • ANNEXURE: Key highlights of the warning letter
  • LUPIN LIMITED :Potential of Complex Generics and Gavis Integration Yet to Unfold
  • Table 1: Lupin Limited
  • NET SALES MIX: 2QFY16
  • Figure 1: Lupin Limited
  • COMBINED ENTITY: LUPIN + GAVIS
  • Figure 1: Lupin Limited
  • COMBINED ENTITY: LUPIN + GAVIS
  • Figure 2: Lupin Limited
  • INCREASED COMPETITION LED TO DECLINED MARKET SHARE IN US
  • Table 2: Lupin Limited
  • US APPROVALS IN 9MFY16
  • Table 3: Lupin Limited
  • US: SELECT UPCOMING ANDAs OPPORTUNITIES
  • Annexure I: Lupin Limited
  • 2QFY16: SALES BREAKUP, GEOGRAPHY-WISE
  • Annexure III: Lupin Limited
  • COMBINED CAPABILITIES: GAVIS + LUPIN
  • NATCO PHARMA: Leading Oncology Company In India - Targeting US market with less competitive and high complex Drugs
  • Table 1: NATCO Pharma
  • KEY ANDAs PIPELINE
Back to Top